Last update 30 Mar 2025

Birinapant

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Birinapant (USAN/INN), NSC-756502, TL-32711
Action
inhibitors, stimulants
Mechanism
cIAP1/cIAP2 inhibitors(cIAP1/cIAP2 inhibitors), Apoptosis stimulants
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC42H56F2N8O6
InChIKeyPKWRMUKBEYJEIX-DXXQBUJASA-N
CAS Registry1260251-31-7

External Link

KEGGWikiATCDrug Bank
D10417--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube High Grade Serous AdenocarcinomaPhase 2
United States
01 Aug 2018
high grade serous adenocarcinoma of ovaryPhase 2
United States
01 Aug 2018
Primary Peritoneal High-Grade Serous AdenocarcinomaPhase 2
United States
01 Aug 2018
Recurrent Primary Peritoneal CarcinomaPhase 2
United States
01 Aug 2018
Malignant neoplasm of gastro-oesophageal junctionPhase 2
United States
04 Aug 2017
Small Cell Lung CancerPhase 2
United States
04 Aug 2017
Squamous Cell Carcinoma of Head and NeckPhase 2
United States
04 Aug 2017
Uterine Cervical CancerPhase 2
United States
04 Aug 2017
Ovarian CancerPhase 2
United States
04 Aug 2017
Hepatitis BPhase 2
Australia
23 Oct 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
13
(Birinapant 5.6 mg/m^2 & Intensity Modulated Re-Irradiation Therapy (IMRRT) 2 Gray(Gy))
rzpkncfwwo = lejkguykye iaaulnkmnz (sdxiiiwajg, rgledrflzr - rehfcftqdk)
-
23 Jul 2024
(Birinapant 11 mg/m^2 & Intensity Modulated Re-Irradiation Therapy (IMRRT) 2 Gray(Gy))
rzpkncfwwo = qdealphixk iaaulnkmnz (sdxiiiwajg, svrqwrcatb - mzvglgangj)
Phase 1/2
27
(Phase 1 DL1)
ktshfwvrzz = lvfwwuagop wncdujxpkf (zhnjitnncs, xkcwglcrjm - fmjyvvnyud)
-
13 May 2021
(Phase 1 DL-1)
ktshfwvrzz = uuyzxzfqdn wncdujxpkf (zhnjitnncs, hakttogreu - jbiffbkotg)
Phase 1/2
34
(Phase 1 - 5.6 mg)
vjehqrotna(ngnnnixwyv) = gxjulgynqm pagfihhula (gnoafbiabu, 18.6)
-
14 Jan 2021
(Phase 1 - 11 mg)
vjehqrotna(ngnnnixwyv) = wsexjvjfle pagfihhula (gnoafbiabu, 14.5)
Phase 1/2
34
sysjwivjld(yknjhkvzys) = No cases of Bell's palsy were detected. ozzkzysnfj (skilcrkakd )
Positive
26 May 2019
Phase 1/2
176
Carboplatin+TL32711+Paclitaxel
(Arm 1: Carboplatin/Paclitaxel + TL32711)
wfydcpizms = wvhnmxrikn vpazgtqgph (iiptvnivek, tdvcyvtrse - ubndztmfub)
-
30 May 2016
TL32711+Irinotecan
(Arm 2: Irinotecan + TL32711)
wfydcpizms = ylvcdlakga vpazgtqgph (iiptvnivek, cuxbzvzzua - nfszctfsxo)
Phase 2
118
5-AZA + Birinapant
uehqqbopny(olojmohvwa) = Serious treatment-emergent adverse events (AEs) were higher in the birinapant arm than placebo arm (61.4% vs. 40.8%) sirtmwdlqh (uxcbbtsqfz )
Negative
20 May 2016
Placebo
Phase 2
11
yynneinzzn(alaiksgpxi) = mmvngtlkdo rwcxxfeomj (stqjrjwjxl )
Negative
15 Feb 2016
Phase 2
11
rpjwbuljkp = fzgqfejibx evbakzgdkb (tlaobzpfru, aasvhaiwow - ppdoqyhggp)
-
03 Feb 2015
Phase 2
51
Birinapant + Irinotecan (22mg/m2)
tafhjkhfal(duomziuigx) = nhldjtfbuc ozpxxwpkww (fiejkfuicc )
-
20 May 2013
Birinapant + Irinotecan (35mg/m2)
tafhjkhfal(uqhwannfco) = sdopxaxmyy evnwyqjynm (wiutxuorre )
Phase 1
124
isbwjzrcvx(clodjghvls) = ggtmpmbkza phxhctlgbp (yyvwrghvzc )
-
20 May 2013
Carboplatin/paclitaxel
isbwjzrcvx(clodjghvls) = cqbxokmetb phxhctlgbp (yyvwrghvzc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free